DarioHealth Corp. Announces Board and Executive Changes

Ticker: DRIO · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1533998

Dariohealth CORP. 8-K Filing Summary
FieldDetail
CompanyDariohealth CORP. (DRIO)
Form Type8-K
Filed DateMar 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, board-of-directors, executive-appointments

TL;DR

DarioHealth shakes up leadership, new directors in, some execs out.

AI Summary

DarioHealth Corp. announced on March 12, 2025, changes in its board and executive team, including the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements. The company, formerly known as LabStyle Innovations Corp., is incorporated in Delaware and headquartered in New York.

Why It Matters

Changes in leadership and board composition can signal shifts in company strategy or financial direction, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, potentially impacting the company's stability and performance.

Key Players & Entities

FAQ

What specific roles have been affected by the departure of officers or directors?

The filing indicates the departure of certain officers and directors but does not specify the exact roles in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on March 12, 2025.

What was DarioHealth Corp.'s former name?

DarioHealth Corp.'s former name was LabStyle Innovations Corp.

In which state is DarioHealth Corp. incorporated?

DarioHealth Corp. is incorporated in Delaware.

What are the principal executive offices of DarioHealth Corp.?

The principal executive offices are located at 322 W. 57th St, #33B, New York, New York 10019.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding DarioHealth Corp. (DRIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing